Infectious disease
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.
Bharat will conduct Phase IV studies to check real-world efficacy against the virus, while Ocugen says Covaxin will be a valuable tool in helping to end the COVID-19 pandemic.
Newcastle University researchers identified a gene, HLA-DRB1*04:01, which was three times more common in asymptomatic COVID-19 patients than in people with symptomatic disease.
The first human case of H10N3 avian flu was diagnosed in China in late May. Chinese health authorities claim a low risk of contagion. Learn more about it here.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 8, 2021.
While several countries rely on Sinovac Biotech to end the pandemic, concerns regarding the shot’s efficacy continue to shroud the vaccine. Currently, it is the second most used vaccine worldwide.
REGEN-COV’s 1,200 mg dose is authorized to treat mild-to-moderate COVID-19 in adults and children 12 years and older who weigh 40 kilograms or more.
Importantly, the researchers recovered virus that they were able to culture, indicating a high risk for transmissibility.
A flurry of COVID-19 research news came out today. Here’s a look.
PRESS RELEASES